Search

Displaying results 9171 - 9180 of 10000 in total
  1. Drug

    Uric acid

    go.drugbank.com/drugs/DB08844
    Investigational

    In one country, Spain, uric acid is an investigational drug in a phase 3 trial studying its effects as an adjunct to alteplase in acute ischemic stroke. … As a therapeutic agent, it is known that uric acid is increased in response to oxidative stress, and as such, uric acid acts as an antioxidant.

    Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household setting
  2. Drug

    Guvacine

    go.drugbank.com/drugs/DB08848
    Experimental

    Guvacine is a pyridine alkaloid found in the Areca nut (also known as the Betel nut). It is an experimental drug with no approved indication. … Currently it has been determined that guvacine is a specific GABA reuptake inhibitor with no significant affinity at GABA receptors.

    Categories: Heterocyclic Compounds, 1-Ring
  3. Drug

    Nipecotic acid

    go.drugbank.com/drugs/DB08849
    Experimental

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Leukotriene C4

    go.drugbank.com/drugs/DB08855
    Experimental

    The conjugation product of LEUKOTRIENE A4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. It stimulates mucus secretion in the lung, and produ...

    Synonyms: (R-(R*,S*-(E,E,Z,Z)))-N-(S-(1-(4-Carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraenyl)-N-L-gamma-glutamyl-L-cysteinyl)glycine, L-γ-glutamyl-S-[(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]pentadeca-2,4,6,9-tetraen-1-yl]-L-cysteinylglycineCategories: SRS-A
  5. Drug

    Bamet-UD2

    go.drugbank.com/drugs/DB08857
    Experimental

    Bamet-UD2 is a novel bile acid-platinum derivative.

  6. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement

    Synonyms: (R)-crizotinibCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  7. Drug

    Brentuximab vedotin

    go.drugbank.com/drugs/DB08870
    ApprovedInvestigational

    Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). … [L1737] The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: ADCETRIS®, ADCETRIS 50 MG IV INFÜZYONLUK ÇÖZELTI KONSANTRESI IÇIN TOZ IÇEREN FLAKON ,FLAKON, 1 ADET
  8. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. … [L11575] Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation.

    Synonyms: Tiacumicin BCategories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  9. Drug

    Taliglucerase alfa

    go.drugbank.com/drugs/DB08876
    Approved

    Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. … It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.

    Synonyms: prGC-DProducts: ELELYSO 200 U İNFÜZYONLUK SOLÜSYON İÇİN LİYOFİLİZE TOZ, 1 ADET
  10. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.

    Categories: Decreased B Lymphocyte Activation, B Lymphocyte Stimulator-specific InhibitorProducts: BENLYSTA 200 MG / 1 ML, BENLYSTA SUBCUTÁNEO 200 MG / 1 ML